Clinically, although CH mutations did not affect phenotypic heterogeneity or disease severity of VEXAS syndrome, presence of either DNMT3A or TET2 mutations increased the risk of mortality by 2 to 14-fold. This evidence concerns the gene C4B and VEXAS syndrome.